Repligen Analyst Price Targets - Benzinga

Repligen Corp

RGENNASDAQ

Trade with Public

Trade with Public

$187.83

3.141.7%

Dern. MÀJ: Oct 29, 1:26 PM

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Repligen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Repligen (RGEN).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$181Upside to Avg. PT-3.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$185→$200
Oct 19, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$145→$180
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$175→$225
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$195→$225
Jul 30, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$180→$185
Jul 29, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$165→$175
Jul 7, 2026	Benchmark	Robert Wasserman	Upgrade	Hold→Buy	$185
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$150→$160
Jun 3, 2026	HSBC	Sidharth Sahoo	PT Cut	Buy	$170→$150
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	$145
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$160
May 6, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$180→$165
May 6, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$145→$160
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$165→$145
Apr 17, 2026	Roth Capital	Natalya Davies	Initiate	Buy	$160
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$175→$145
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$140
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$180→$208
Feb 25, 2026	UBS	Dan Leonard	PT Cut	Buy	$200→$195
Feb 25, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$200→$175

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Repligen, Raises Price Target to $200

RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $185 to $200.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $180

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and raises the price target from $145 to $180.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Repligen, Raises Price Target to $225

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185

Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $180 to $185.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $165 to $175.

Benzinga Newsdesk